Insider Makes Significant Stock buy in Odonate Therapeutics (ODT) Shares Extends the Trend of Last 90 Days

Thursday, February 22, 2018 10:15 PM ET

Insider Makes Significant Stock buy in Odonate Therapeutics (ODT) Shares Extends the Trend of Last 90 Days

One Odonate Therapeutics insider — Kevin C Tang, 10% Owner, Director and Officer — today, acquired 39,083 shares having a market value of approximately $1,061,811, as revealed in a form 4 document filed with the SEC. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the purchase of 128,255 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 167,338 shares and have averaged 83,669 shares per transaction over this time period.

Over the last 90 days, the number of insider buy/sell trades at Odonate Therapeutics is greater than its 119-company peer group average. The Pharmaceuticals peer group saw 66 buy/sell trades during this period for an average of 0.6 transactions per company. However, the number of shares traded per transaction by Odonate Therapeutics insiders is lower than its peers. Within the peer group there were 1,828,831 shares purchased and 4,299,976 shares sold with company insiders selling 37,442 shares on average over this time period.

The data sourced in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.